Corning Announces Significant Milestone in High-Throughput Label-Free Screening for Drug Development
News Jun 13, 2008
Corning Incorporated has announced the completion of two independent high-throughput label-free screens believed to be the largest ever publicly announced label-free screens to date.
Scientists from two of the top 10 pharmaceutical companies each screened 100,000 drug candidates in high throughput using the label-free Corning® Epic® System. These two screens represent a major milestone in accelerating drug discovery using label-free technology.
“Our customers have demonstrated true high-throughput label-free screening – a goal that has eluded label-free researchers for many years,” said Ron Verkleeren, Epic business director, Corning Incorporated.
“Removing fluorescent, luminescent and radioactive labels from assays promises to improve the speed and quality of the drug discovery process,” he continued. “It can open up a wider variety of drug targets and enable researchers to study drug candidates in more physiologically relevant systems. These screens exemplify the remarkable progress label-free technology has made in the last few years and the significant impact it can have in the future.”
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
Synthesis of Drug-Like Molecules Simplified Using New Cross-Coupling MethodNews
Researchers have designed a new molecule-building method. The technique, described recently in the journal Science, paves the way toward other new chemical reactions and facilitates the synthesis of pharmaceutically-relevant molecules.READ MORE
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
Comments | 0 ADD COMMENT
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
World Congress on Advances in Addiction Science and Medicine
Sep 24 - Sep 25, 2018
10th International Conference on Mass Spectrometry and Chromatography
Oct 08 - Oct 09, 2018